Cancer reports最新文献

{"title":"m6A-Mediated Methylation Patterns and Their Association With Obstructive Sleep Apnea in Lung Adenocarcinoma","authors":"Lei Xia,&nbsp;Zhuodong Chai,&nbsp;Xiaoying Wei,&nbsp;Yuan Wei,&nbsp;Daxiong Zeng,&nbsp;Junhong Jiang,&nbsp;Jing Li","doi":"10.1002/cnr2.70344","DOIUrl":"https://doi.org/10.1002/cnr2.70344","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Epigenetic regulation significantly affects immune responses in lung adenocarcinoma (LUAD). However, the role of RNA N6-methyladenosine (m6A) modification, especially in obstructive sleep apnea-hypopnea syndrome (OSAHS) within LUAD, is not well understood.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This study examined m6A modification patterns in 973 LUAD patients using 23 regulatory genes. Unsupervised clustering categorized patients by m6A profiles, quantified by an m6A score. Associations with clinical outcomes, including survival, immune infiltration, tumor microenvironment, OSAHS incidence, and drug sensitivity, were analyzed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>m6A regulator mutations were linked to LUAD, revealing two distinct modification patterns and three gene clusters, all tied to immune phenotypes and clinical outcomes. Higher m6A scores correlated with lower survival, more frequent OSAHS, and increased immune activity. Patients with high m6A scores were more sensitive to PD-L1/PD-1 inhibitors and Phenformin, while those with low scores responded better to Cisplatin, Epothilone B, and Talazoparib.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Analyses confirmed m6A modification's role in LUAD progression, immune regulation, and outcomes. The m6A score is a valuable prognostic marker associated with survival, OSAHS incidence, and drug sensitivity. These findings highlight m6A's potential as a therapeutic target and biomarker, particularly for LUAD patients with OSAHS.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 9","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70344","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145012207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic Challenges and Influencing Factors in Non-Melanoma Skin Cancers: A Retrospective Analysis of Basal Cell Carcinoma and Squamous Cell Carcinoma Cases","authors":"Nicholas Florin Kormos,&nbsp;Ioana Daria Paval,&nbsp;Carina Maria Petrenciu,&nbsp;Alin Stefan Vizitiu,&nbsp;Adrian Lucian Baican","doi":"10.1002/cnr2.70332","DOIUrl":"https://doi.org/10.1002/cnr2.70332","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Non-melanoma skin cancers (NMSC) are the most frequent cutaneous tumors globally. Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) represent the most frequently encountered representatives of this group and may represent a diagnosis challenge in some circumstances of hard to differentiate tumors.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>The aim of this study was to determine the factors that influence the diagnosis of NMSC and their impact.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>A single center, descriptive, retrospective study was performed, with a total of 866 tumors excised from 678 patients between 2016 and 2022. Cases were then analyzed based on their histological diagnosis and characteristics and the available clinical data. From the 866 cases, 709 were histologically diagnosed as BCC and 157 as SCC. The clinical accuracy for BCCs was 95% whereas for SCCs was 62% with both having large variations among attending dermatologists. Clinical factors that were found to influence the diagnosis were: advanced age (<i>p</i> ⟨ 0.001), a biopsy beforehand (<i>p</i> = 0.009), and multiple diagnosis or uncertainty (<i>p</i> = 0.005) were predictive for a final diagnosis of SCC. Factors predicting BCCs were: the presence of multiple lesions (<i>p</i> = 0.032), presence of ulcerations (<i>p</i> ⟨ 0.001), age under 50 (<i>p</i> = 0.002). BCCs were more likely to be correctly diagnosed than SCC (<i>p</i> ⟨ 0.001). Cases with multiple BCCs were thinner compared to single-lesion excisions (<i>p</i> ⟨ 0.001). A tumor reduction was observed after the 2020 the SARS-CoV-2 (<i>p</i> = 0.023).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Differentiating NMSC can be challenging, but several trends have been observed which may aid in further improving the diagnosis rates especially for SCCs.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 9","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70332","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144998791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unresectable Primary Enteric-Type Thymic Adenocarcinoma Treated With FOLFOX Chemotherapy: A Case Report","authors":"Carl He,&nbsp;Georgia Bentick,&nbsp;Patrick Hosking,&nbsp;Andrew Mant","doi":"10.1002/cnr2.70318","DOIUrl":"https://doi.org/10.1002/cnr2.70318","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Enteric-type thymic adenocarcinomas are an extremely rare and distinct subtype of thymic malignancies, as classified by the 2021 World Health Organization classification of thymic tumors. These tumors exhibit close molecular and morphologic similarity to primary gastrointestinal malignancies. To date, there are no tailored treatment guidelines for enteric-type thymic adenocarcinoma.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Case&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;A 65-year-old woman was admitted to the Oncology unit of a Melbourne Metropolitan Hospital after presenting with progressive symptoms of thoracic outlet syndrome, where a CT scan identified a localized anterior mediastinal mass measuring up to 7.5 × 6.0 × 6.0 cm (transverse × Anterior–Posterior × Superior–inferior). The mass was deemed unresectable. A core biopsy diagnosed the patient with a primary enteric-type thymic adenocarcinoma, based on positive immunohistochemical staining for the intestinal markers CK20 and CDX2, positive staining for CD5—a marker commonly associated with thymic carcinoma, and positive staining for CK7—a marker not classically expressed in colonic adenocarcinoma. The patient received five fractions of 20 Gray palliative radiotherapy for superior vena cava syndrome, followed by four cycles of Oxaliplatin/5-fluorouracil/leucovorin (FOLFOX) chemotherapy. FOLFOX, a common systemic therapy for gastrointestinal adenocarcinomas, was chosen due to the tumor's enteric profile and was selected over the then-NCCN-recommended carboplatin/paclitaxel regimen, which did not have trial-backed evidence of efficacy in thymic adenocarcinomas, particularly adenocarcinomas of the enteric type. After starting on frontline systemic therapy with FOLFOX, restaging scans after Cycle 3 showed a reduction in the size of her anterior mediastinal mass, which further decreased in size after cycle 4. Treatment was then discontinued per the patient's goals of care; however, follow-up imaging showed ongoing disease stability for 6 months. The patient died of disease 8 months after treatment discontinuation and 13 months after her initial diagnosis.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusion&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;We report the first case of primary enteric-type thymic adenocarcinoma treated at an Australian institution, and the first published case using FOLFOX as frontline systemic therapy in a patient with unresectable primary enteric-type thymic adenocarcinoma. Noting the close molecular resemblance between enteric-type thymic adenocarcinoma and gastrointestinal malignancies, chemotherapy regimens commonly used in the treatment of gastrointestinal cancer may offer a more effective option than standard frontlin","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 9","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70318","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144934882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Case of Hepatosplenic Gamma Delta T Cell Lymphoma With Concomitant Bone Marrow Aplasia Following Azathioprine Therapy, Treatment Course and Review of the Literature","authors":"Rania Younis,&nbsp;Holger Hauspurg,&nbsp;Andreas Voss","doi":"10.1002/cnr2.70334","DOIUrl":"https://doi.org/10.1002/cnr2.70334","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Hepatosplenic T-cell lymphoma (HSTCL) is a rare and aggressive subtype of peripheral T-cell lymphoma with a poor prognosis, primarily affecting young adult males, many with a background of immunosuppression or autoimmune disease.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case</h3>\u0000 \u0000 <p>We present the case of a 27-year-old male previously treated with azathioprine who developed pancytopenia. Bone marrow biopsy revealed severe aplasia with partial infiltration by gamma-delta T-lymphocytes (Tγδ). A definitive diagnosis of HSTCL was established through liver biopsy. The patient received induction chemotherapy with the Ifosfamide, Carboplatin, Etoposide (ICE regimen) but remained pancytopenic, prompting allogeneic stem cell transplantation. Sixty months post-treatment, he remains in complete remission.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>To our knowledge, this is the first reported case of HSTCL presenting concurrently with aplastic anemia in the context of prior azathioprine exposure. The underlying pathophysiology is likely multifactorial, involving both immune-mediated suppression and drug-induced toxicity. Clinicians should maintain a high index of suspicion for lymphoma in patients developing unexplained pancytopenia while on azathioprine therapy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 9","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70334","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144998792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Arjunolic Acid From Terminalia ivorensis A. Chev (Combretaceae) Possesses Anti-Breast Cancer Effects In Vitro and In Vivo","authors":"Muriel Angounou Akamse,&nbsp;Vigny Diembo Kamgo,&nbsp;Patrick Yves Ango,&nbsp;Marthe Carine Djuidje Fotsing,&nbsp;Boris Hugor Pehuie Fomat,&nbsp;Edwin Mmutlane,&nbsp;Ghislain Wabo Fotso,&nbsp;Deccaux Wabo Fotso Gilbert Kapche,&nbsp;Stephane Zingué,&nbsp;Derek Tantoh Ndinteh","doi":"10.1002/cnr2.70337","DOIUrl":"https://doi.org/10.1002/cnr2.70337","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Breast cancer is a major public health issue. In 2022, approximately 4,207 new cases and 2,285 deaths were reported in Cameroon. Given the limited accessibility and various issues associated with conventional treatments, herbal medicine has emerged as a promising alternative. Aims: This study aimed to evaluate the potential anticancer activity of naturally occurring compounds isolated from Terminalia ivorensis A. Chev.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>This was done by fractionating the methanolic extract of T. ivorensis and purifying the constituents obtained using conventional chromatographic techniques. Thereafter, the crude extract and its 5 isolates were subjected to in vitro MTT bioassay to assess their potential to kill human (MCF-7 and MDA-MB-231) and murine (4T1) breast cancer cell lines. Furthermore, the potential of the most active compound (arjunolic acid) to mitigate DMBA-induced breast cancer in rats was tested. Treatments were administered for a period of 121 days; the group of rats treated with arjunolic acid (1 mg/kg) was compared to the group that received tamoxifen at 3.3 mg/kg (standard), as well as to the normal and negative control groups. Key parameters assessed included survival, tumor burden, cytokine profiles, as well as hematological, hepatic, and renal functions. Out of the 5 isolates [lupeol (1), betulinic acid (2), Arjunolic acid (3), 3,3'-Di-O-methylellagic acid-4'-O-β-D-glucopyranoside (4) 3,3’,4’-Tri-O-methylellagic acid-4-O-β-Dglucopyranoside (5)] from T. ivorensis, compound (3) had the most significant inhibitory effect against breast cancer cells growth with an average CC50 of 20 μg/mL. In vivo, a significant reduction (~89%) in tumor burden and favorable modulation of inflammation, characterized by a decrease in pro-inflammatory cytokines (TNF-α, IFN-γ, IL-6, VEGF) and an increase in anti-inflammatory IL-10 was observed. Moreover, treatment with arjunolic acid led to improved survival and maintenance of body weight, without inducing any notable adverse effects.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Arjunolic acid should receive more attention as a candidate for an effective therapeutic option, combining anticancer effects with beneficial anti-inflammatory activity. We encourage further studies on this compound to better understand its mode and mechanism of action.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 9","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70337","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144998793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"YRDC is a Prognostic-Related Biomarker Correlated With Immune Infiltration and Drug Sensitivity in Pan-Cancer","authors":"Li Qiao,&nbsp;Yuetong Zhang,&nbsp;Pin Huang","doi":"10.1002/cnr2.70325","DOIUrl":"https://doi.org/10.1002/cnr2.70325","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>YRDC has emerged as a potential biomarker in cancer, yet its prognostic value, oncogenic mechanisms, role in immune infiltration, and anticancer drugs efficacy in pan-cancer remained poorly understood.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>This study aimed to comprehensively investigate YRDC's role in pan-cancer and to explore the potential effects of YRDC on the immune infiltration pattern and anticancer drug sensitivity.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>Based on bioinformatics analysis of multi-omics data, we firstly demonstrated that YRDC was markedly overexpressed and associated with worse prognosis in various tumors. Further, our results indicated that genetic alterations, copy number variations, and methylation levels of YRDC might explain the different YRDC expression between tumors and controls. Additionally, YRDC might promote cancer via enhancing tumor cell proliferation, modulating immune cell infiltration, and enhancing drug resistance. Notably, YRDC emerged as a potential biomarker for predicting immunotherapy response and targeted drug efficacy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our study identifies YRDC as a novel therapeutic target and a promising biomarker for cancer progression, immunotherapy response, and targeted drug sensitivity across pan-cancers. These findings provide evidence for further research into YRDC's role in cancer biology and future clinical exercises.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 9","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70325","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144929458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Routine Tumor Testing for Homologous Recombination Deficiency in Patients With High Grade Epithelial Ovarian Cancer at a Statewide Gynecological Cancer Service in Western Australia: An Observational Study","authors":"Kaamini Planisamy,&nbsp;Elena Ctori,&nbsp;Benhur Amanuel,&nbsp;Emma R. Allanson,&nbsp;Chloe Ayres,&nbsp;Martin Buck,&nbsp;Giselle Howard,&nbsp;Yee Leung,&nbsp;Tarek Meniawy,&nbsp;G. Raj K. A. Mohan,&nbsp;Cassandra B. Nichols,&nbsp;Navin David Pallayoor,&nbsp;Paul A. Cohen","doi":"10.1002/cnr2.70335","DOIUrl":"https://doi.org/10.1002/cnr2.70335","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Poly-ADP ribose polymerase inhibitors have been shown to improve progression-free survival in patients with advanced high-grade epithelial non-mucinous ovarian cancers characterized by a deficiency in homologous recombination (HRD). Guidelines recommend all patients with advanced high-grade epithelial ovarian cancer undergo genomic tumor testing for HRD. Our aim was to evaluate the first year of HRD testing at the statewide Western Australia Gynecologic Cancer Service to assess factors associated with obtaining a diagnostic HRD testing result.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Retrospective chart review.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>HRD testing was indicated in 84 patients, and ordered in 79, of which three had non-diagnostic/inconclusive results, all due to insufficient tumor quantity. One patient had the sample collected using a 20-gauge core biopsy needle under image guidance, one patient following interval debulking surgery, and one following primary debulking surgery. Of 76 patients with an HRD result, HRD was positive in 29 (38.2%). A somatic <i>BRCA</i> mutation was detected in six of these 29 patients (20.6%) and HRD positive, BRCAwt was detected in 23 of 29 patients (79.4%). All core biopsies with 16- and 18-gauge needles had a diagnostic HRD result. Ten of 11 patients who were treated by neoadjuvant chemotherapy and whose biopsies were obtained at interval cytoreductive surgery had sufficient tumor tissue for testing and had a diagnostic HRD result. All ascitic/pleural fluid samples sent for HRD testing yielded diagnostic results.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Compliance with HRD testing was high, and only three of 79 (3.8%) patients had non-diagnostic results.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 9","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70335","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144927471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rare Case of Scapula Resection for Oligometastatic Colon Carcinoma to Bone","authors":"Shaan Sadhwani,&nbsp;Jamie Henzes,&nbsp;Joshua Harman,&nbsp;Brian Omslaer,&nbsp;Emily Kelly,&nbsp;Lauren Zeitlinger","doi":"10.1002/cnr2.70310","DOIUrl":"https://doi.org/10.1002/cnr2.70310","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Colorectal carcinoma with isolated metastasis to the scapula is a rare occurrence. There is a paucity of accounts detailing experience with this unique scenario. We present a case of oligometastatic colon adenocarcinoma to the scapula with subsequent scapulectomy, in which the patient had eventual visceral disease recurrence yet still gained a palliative benefit from the procedure.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case</h3>\u0000 \u0000 <p>We detail the account of a patient with metastatic colorectal carcinoma to the right scapula and subsequent treatment for the scapular metastasis. The patient underwent successful total scapulectomy for metastatic colon adenocarcinoma with negative margins achieved. He had an uneventful postoperative course and was discharged home on day three. Upon follow-up after total scapulectomy, the patient experienced significant symptom improvement and functional recovery.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>We believe a significant benefit to the patient's overall quality of life was provided by undergoing this procedure. Therefore, this option should remain part of the oncologic surgeon's armamentarium to offer a palliative option to patients with the goal of controlling pain and retaining function.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 9","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70310","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144923606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune Reconstitution and Need for Booster Vaccinations Among Non-Transplant Childhood Cancer Survivors: A Single-Center Experience","authors":"Esther Shin,&nbsp;Haesol Han,&nbsp;Kenneth J. Nobleza,&nbsp;Jonathan D. Crews,&nbsp;Araceli Elizalde,&nbsp;Nadia Cheek,&nbsp;Julie Voeller","doi":"10.1002/cnr2.70326","DOIUrl":"https://doi.org/10.1002/cnr2.70326","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Waning immunity from childhood vaccines can be more profound in pediatric patients following chemo/immunotherapy. Moreover, childhood cancer survivors (CCS) are at significantly increased risk for life-threatening infections. We implemented an institutional standard of practice (SOP) to assess immune reconstitution and provide recommendations for re-vaccination for non-transplant CCS.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A lymphocyte mitogen proliferation panel was obtained at around 6 months off therapy to assess non-specific lymphocyte proliferation to phytohemagglutinin (PHA), concanavalin A (Con A), and pokeweed mitogen (PWM). Serologic concentrations of immunoglobulin G (IgG) antibodies were measured for hepatitis B (hepB) virus, tetanus toxoid, and <i>Streptococcus pneumoniae</i>. Booster vaccines were recommended for seronegative patients. Catch-up vaccines were recommended for CCS not previously up to date.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>All evaluated patients were considered immune reconstituted at 6 months off therapy. Most patients (about 80%) were seronegative for hepB virus and <i>S. pneumoniae</i>, but nearly 100% retained immunity against tetanus. Most patients had positive seroconversion with a single booster vaccination with hepB (86%) and PPSV23 (76%). There were missed opportunities with each step of the institutional SOP due to provider omission with varying degrees depending on the provider.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This study suggests that most CCS are ready for re-immunization with inactivated vaccines by 6 months of therapy and underscores the need for boosters to optimize protection against vaccine-preventable infections. Future studies are needed to inform consensus guidelines adapted to patient age, underlying cancer diagnosis, and treatment intensity.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 9","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70326","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144923394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of a Machine Learning Model Integrating Pathomics and Clinical Data to Predict Axillary Lymph Node Metastasis in Breast Cancer: A Two-Center Study","authors":"Long Wang,&nbsp;Fanli Qu,&nbsp;Ping Wen,&nbsp;Yu Luo,&nbsp;Huan Zhang,&nbsp;Shanqi Li,&nbsp;Xuedong Yin,&nbsp;Yulan Zhao,&nbsp;Xiaohua Zeng","doi":"10.1002/cnr2.70302","DOIUrl":"https://doi.org/10.1002/cnr2.70302","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Accurately assessing the status of axillary lymph nodes (ALNs) is essential for devising optimal surgical plans and making informed treatment decisions in breast cancer (BC) patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>This study aims to develop an innovative nomogram based on pathomics to preoperatively predict ALN metastasis (ALNM) in BC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>Our study performed a retrospective analysis on digital hematoxylin and eosin (H&amp;E)-stained images obtained from 407 patients across two institutions who were allocated into a training cohort (TC; <i>n</i> = 203), an internal validation cohort (IVC; <i>n</i> = 136), and an external validation cohort (EVC; <i>n</i> = 68). Initially, the Mann–Whitney <i>U</i>-test and Spearman's rank correlation coefficient were utilized for feature selection, employing the least absolute shrinkage and selection operator (LASSO) regression for further refinement. For the evaluation of the predictive value of ALNM and other clinicopathological factors, we deployed both univariate (ULR) and multivariate (MLR) logistic regression analyses. Among the six machine learning (ML) algorithms, logistic regression, which demonstrated the highest area under the curve (AUC) value, was employed to establish the final nomogram model. The nomogram reliability and stability were assessed by analyzing the AUC of the receiver operating characteristic (ROC) curve, decision curve analysis (DCA), and calibration plots. MLR analysis demonstrated estrogen receptor (ER), human epidermal growth factor receptor 2 (HER2), tumor size, and pathomics features as independent ALNM predictors. The nomogram demonstrated that the AUC in the IVC (0.783) surpassed that of the Path-score model (0.698) (DeLong test, <i>p</i> = 0.008558). Similarly, in the EVC, the nomogram surpassed the clinical model regarding AUC (0.738 vs. 0.574; DeLong test, <i>p</i> = 0.00494). Additionally, DCA analysis indicated a net clinical benefit associated with the nomogram.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our study demonstrates the effectiveness of pathomics features in predicting ALNM in BC patients. Furthermore, the pathomics-based nomogram offers a valuable tool for personalized treatment planning in this patient population.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 9","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70302","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144923374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}